High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference

被引:102
作者
Piketty, Marie-Liesse [1 ]
Prie, Dominique [1 ]
Sedel, Frederic [2 ]
Bernard, Delphine [2 ]
Hercend, Claude [1 ]
Chanson, Philippe [3 ,4 ]
Souberbielle, Jean-Claude [1 ]
机构
[1] GH Necker Enfants Malades, Serv Explorat Fonct, 149 Rue Sevres, F-75743 Paris 15, France
[2] MedDAY Pharmaceut, Paris, France
[3] Hop Univ Paris Sud, Hop Bicetre, AP HP, Serv Endocrinol & Malad Reprod, Le Kremlin Bicetre, France
[4] Univ Paris Sud, Univ Paris Saclay, Fac Med Paris Sud, INSERM 1185, Le Kremlin Bicetre, France
关键词
biotin; hyperthyroidism; immunoassay; interference; multiple sclerosis; PROGRESSIVE MULTIPLE-SCLEROSIS; GRAVES-DISEASE; VITAMIN-D; HYPERTHYROIDISM; IMMUNOASSAYS; TESTOSTERONE; FATIGUE; ASSAY; SERUM;
D O I
10.1515/cclm-2016-1183
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: High-dose biotin therapy is beneficial in progressive multiple sclerosis (MS) and is expected to be adopted by a large number of patients. Biotin therapy leads to analytical interference in many immunoassays that utilize streptavidin-biotin capture techniques, yielding skewed results that can mimic various endocrine disorders. We aimed at exploring this interference, to be able to remove biotin and avoid misleading results. Methods: We measured free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), parathyroid homrone (PTH), 25-hydroxyvitamin D (25OHD), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, C-peptide, cortisol (Roche Diagnostics assays), biotin and its main metabolites (liquid chromatography tandem mass spectrometry) in 23 plasmas from MS patients and healthy volunteers receiving high-dose biotin, and in 39 biotin-unsupplemented patients, before and after a simple procedure (designated N5) designed to remove biotin by means of streptavidincoated microparticles. We also assayed fT4, TSH and PTH in the 23 high-biotin plasmas using assays not employing streptavidin-biotin binding. Results: The biotin concentration ranged from 31.7 to 1160 mu g/L in the 23 high-biotin plasmas samples. After the N5 protocol, the biotin concentration was below the detection limit in all but two samples (8.3 and 27.6 mu g/L). Most hormones results were abnormal, but normalized after N5. All results with the alternative methods were normal except two slight PTH elevations. In the 39 biotinunsupplemented patients, the N5 protocol did not affect the results for any of the hormones, apart from an 8.4% decrease in PTH. Conclusions: We confirm that most streptavidin-biotin hormone immunoassays are affected by high biotin concentrations, leading to a risk of misdiagnosis. Our simple neutralization method efficiently suppresses biotin interference.
引用
收藏
页码:817 / 825
页数:9
相关论文
共 26 条
  • [1] Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses
    Barbesino, Giuseppe
    [J]. THYROID, 2016, 26 (06) : 860 - 863
  • [2] Biotin interference in immunoassays mimicking subclinical Graves' disease and hyperestrogenism: a case series
    Batista, Marcelo C.
    Ferreira, Carlos E. S.
    Faulhaber, Adriana C. L.
    Hidal, Jairo T.
    Lottenberg, Simao A.
    Mangueira, Cristovao L. P.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (06) : E99 - E103
  • [3] Low testosterone is associated with disability in men with multiple sclerosis
    Bove, R.
    Musallam, A.
    Healy, B. C.
    Raghavan, K.
    Glanz, B. I.
    Bakshi, R.
    Weiner, H.
    De Jager, P. L.
    Miller, K. K.
    Chitnis, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (12) : 1584 - 1592
  • [4] Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation
    Burfeind, Kevin G.
    Yadav, Vijayshree
    Marks, Daniel L.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (11)
  • [5] Factitious Graves' Disease Due to Biotin Immunoassay Interference-A Case and Review of the Literature
    Elston, Marianne S.
    Sehgal, Shekhar
    Du Toit, Stephen
    Yarndley, Tania
    Conaglen, John V.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (09) : 3251 - 3255
  • [6] Foroughipour A, 2012, J RES MED SCI, V17, P882
  • [7] Estrogen and testosterone therapies in multiple sclerosis
    Gold, Stefan M.
    Voskuhl, Rhonda R.
    [J]. NEUROTHERAPY: PROGRESS IN RESTORATIVE NEUROSCIENCE AND NEUROLOGY, 2009, 175 : 239 - 251
  • [8] Interference by biotin therapy on measurement of TSH and FT4 by enzyme immnnoassay on boehringer Mannheim ES700 analyser
    Henry, JG
    Sobki, S
    Arafat, N
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 1996, 33 : 162 - 163
  • [9] Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?
    Holmoy, Trygve
    Torkildsen, Oivind
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (03) : 233 - 235
  • [10] Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study
    Joly, Dominique
    Drueke, Tilman B.
    Alberti, Corinne
    Houillier, Pascal
    Lawson-Body, Ethel
    Martin, Kevin J.
    Massart, Catherine
    Moe, Sharon M.
    Monge, Marie
    Souberbielle, Jean-Claude
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (06) : 987 - 995